CSL Behring L.L.C.

CSL Behring L.L.C., doing business as CSL Behring LLC, is a global biotherapeutics company headquartered in King of Prussia, Pennsylvania, that specializes in plasma-derived and recombinant therapies. The company is registered as a foreign-owned, for-profit corporate entity with the federal government and has maintained active registration in SAM.gov since March 2002. CSL Behring supplies critical specialty pharmaceutical products to the Department of Veterans Affairs through multiple federal contract vehicles, with a primary focus on providing hereditary angioedema treatments and related hematology products to support the healthcare needs of veterans across the nation.

Through its federal contract activities, CSL Behring L.L.C. has primarily delivered HAEGARDA, a C1 inhibitor medication used to treat hereditary angioedema, along with related plasma-derived and recombinant therapies including Privigen, Hizentra, and Kcentra. The company has received numerous delivery orders and blanket purchase agreement calls from the Department of Veterans Affairs, with contract awards spanning from 2021 through 2025 across multiple Veterans Integrated Service Networks including VISN 7, VISN 8, VISN 9, VISN 17, VISN 19, and VISN 22. These delivery orders and task orders have ranged in value from approximately $16,600 to $391,600, with the majority designated for emergency pharmaceutical procurement and routine supply needs at VA medical facilities nationwide. All awards have been issued under firm fixed pricing arrangements with no set-aside designations applied, reflecting CSL Behring's status as a large enterprise contractor. The company serves as the prime contractor on all identified awards, with no subcontractors noted in the contract documentation, and performance of all work occurs at CSL Behring's manufacturing and distribution facility in King of Prussia, Pennsylvania.

CSL Behring L.L.C. holds three significant Indefinite Delivery Vehicles with the federal government, all supporting the supply of specialty pharmaceuticals to the Veterans Health Administration. The primary IDV is a Federal Supply Schedule contract (FSS-61-IB) for Pharmaceuticals and Drugs, awarded on September 30, 2021, by Veterans Integrated Service Network 12 with a ceiling value of $201.48 million and validity through September 29, 2026. Under this multiple-award GSA schedule, CSL Behring supplies critical pharmaceutical products through task orders issued by various Veterans Integrated Service Networks. The company also maintains a single-award Blanket Purchase Agreement specifically for HAEGARDA procurement, awarded by the National Acquisition Center on September 30, 2021, with a $17.5 million ceiling through September 29, 2026, which serves as the primary vehicle for coordinated supply of this medication across the VA system. Additionally, CSL Behring holds a smaller single-award BPA with Veterans Integrated Service Network 7 for HAEGARDA 2000 and 3000 unit/vial medications, valued at $113,280 with performance through June 30, 2023. These IDVs enable efficient procurement of specialty pharmaceuticals by affiliated VA medical centers through pre-negotiated pricing and terms, facilitating rapid access to critical treatments for veterans with rare and complex medical conditions.